Monoclonal antibodies: Trends in therapeutic success and commercial focus

被引：36

作者：

Kinch, Michael S. ^{[1
]}

Kraft, Zachary ^{[1
]}

Schwartz, Tyler ^{[1
]}

机构：

[1] Long Isl Univ, Ctr Res Innovat Biotechnol, Brookville, NY 11548 USA

来源：

DRUG DISCOVERY TODAY | 2023年 / 28卷 / 01期

关键词：

monoclonal antibodies; biologics; clinical trials; mechanism of action; DRUG DEVELOPMENT;

D O I：

10.1016/j.drudis.2022.103415

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Monoclonal antibody products have risen from obscurity in the 1990s to a position that increasingly dominates both revenue generation and patient impact. This success has occurred largely over the past two decades, and we have identified factors associated with the remarkable advances that have contributed to the discovery, development and approval of monoclonal antibodies. Although consolidation has increased in recent years, the net number of monoclonal antibody developers continues to grow, bucking the general trend in the biopharmaceutical industry.

引用

页数：10

共 31 条

[1] Hybridoma technology: a view from the patent arena [J].

Ansell, PRJ .

IMMUNOLOGY TODAY, 2000, 21 (08) :357-358

[2] Rejection of Aducanumab (Aduhelm) by the Health Care Community Lessons Learned and the Path Ahead [J].

Bauchner, Howard ;

Alexander, G. Caleb .

MEDICAL CARE, 2022, 60 (05) :392-393

[3] Monoclonal antibody therapeutics: history and future [J].

Buss, Nicholas A. P. S. ;

Henderson, Simon J. ;

McFarlane, Mary ;

Shenton, Jacintha M. ;

de Haan, Lolke .

CURRENT OPINION IN PHARMACOLOGY, 2012, 12 (05) :615-622

[4] The pharmacology and therapeutic applications of monoclonal antibodies [J].

Castelli, Maria Sofia ;

McGonigle, Paul ;

Hornby, Pamela J. .

PHARMACOLOGY RESEARCH & PERSPECTIVES, 2019, 7 (06) :e00535

[5]

Citeline, 2021, CLIN DEV SUCCESS RAT

[6] Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy [J].

Cruz, Esteban ;

Kayser, Veysel .

BIOLOGICS-TARGETS & THERAPY, 2019, 13 :33-51

[7] Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs [J].

DiMasi, J. A. ;

Feldman, L. ;

Seckler, A. ;

Wilson, A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (03) :272-277

[8] Process economics of industrial monoclonal antibody manufacture [J].

Farid, Suzanne S. .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 848 (01) :8-18

[9] The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA [J].

Gherghescu, Ioana ;

Delgado-Charro, M. Begona .

PHARMACEUTICS, 2021, 13 (01) :1-16

[10] Recombinant protein and therapeutic monoclonal antibody drug development in the United States from 1980 to 1994 [J].

Gosse, ME ;

DiMasi, JA ;

Nelson, TF .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (06) :608-618

← 1 2 3 4 →